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Abstract
Biodegradable polydioxanone stents were developed 
for the treatment of refractory benign esophageal stric-
tures but have been suggested as a new therapeutic 
option for intestinal strictures. The primary advantage 
of biodegradable stents over self-expandable metal-
lic stents is that removal is not required. There are, 
however, few data available on their use in the small or 
large bowel. We herein describe the case of a 33-year-
old patient with long-standing Crohn’s disease (CD) 
who developed a fibrotic stricture of the sigmoid too 
long to be amenable to balloon dilation. The use of 
a biodegradable polydioxanone stent was chosen to 
avoid surgery. Combined endoscopic and fluoroscopic 
placement of the stent was technically simple, safe and 
clinically successful, and no recurrence of obstructive 
symptoms occurred during a 16-mo follow-up. Further 
studies are needed to evaluate the long-term efficacy 
and safety of biodegradable stents in the treatment of 
intestinal strictures, particularly in the context of CD.
© 2013 Baishideng. All rights reserved.
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Core tip: Strictures in Crohn’s disease (CD) are chal-
lenging. Until the development of medical therapy that 
can prevent or reverse intestinal fibrosis, endoscopic 
management is recommended to avoid surgery. Bio-
degradable polydioxanone stents originally developed 
to treat refractory esophageal benign strictures are a 
promising alternative to balloon dilation with the ad-
vantage over metallic stents that they do not need to 
be removed. However, data on their use in the bowel is 
limited to a few series, mostly in patients with postsur-
gical colorectal strictures. We report the case of a CD 
patient presenting with a symptomatic colonic fibrotic 
stricture that was successfully treated with a biodegrad-
able stent.
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INTRODUCTION
Strictures are a common complication of  Crohn’s disease 
(CD), occurring in 1/3 of  patients after 10 years of  dis-
ease. They occur most frequently in the ileocecal region 
and rectum and at anastomotic sites where the disease 
is likely to recur[1]. Medical therapy has not been shown 
to be effective in the treatment of  fibrotic strictures, and 
its role in preventing stricture formation has been disap-
pointing[2]. As disease recurrence is common, endoscopic 
methods, such as balloon dilation or stenting for refrac-
tory strictures, have been advocated to decrease surgery. 
Biodegradable stents were originally developed to 
treat refractory benign esophageal strictures but are a 
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promising therapeutic option for intestinal strictures 
because they do not require removal and may be able to 
overcome some of  the drawbacks of  self-expandable 
metallic stents (SEMS). We report our experience with 
the off-label use of  a biodegradable esophageal polydiox-
anone stent in the management of  a colonic stricture 
complicating CD.
CASE REPORT
A 33-year-old female with a history of  CD was admitted 
to the hospital in February 2011 with abdominal cramps, 
constipation and air-fluid levels in the small and large 
bowel on X-ray. The CD diagnosis had been established 
at age 16 years. The disease involved the terminal ileum, 
colon and perianal region and presented with an inflam-
matory behavior (A1L3B1p according to the Montreal 
classification)[3,4]. She was initially treated with oral corti-
costeroids and started on azathioprine, but in 2001 inf-
liximab was added for persistent symptoms. The patient 
experienced some flares over the years until 2009, when 
she achieved sustained clinical and endoscopic remission 
while on azathioprine at 3 mg/kg per day and infliximab 
at 5 mg/kg every 4 wk.
The laboratory results were unremarkable with no 
signs of  systemic inflammation. A computed tomog-
raphy scan revealed concentric wall thickening over 6 
cm lengths in the sigmoid colon with narrowing of  the 
lumen and prestenotic dilation but no regional lymph-
adenopathy. The bowel obstruction resolved with naso-
gastric tube suction and intravenous fluids. Colonoscopy 
confirmed the existence of  a distal sigmoid stricture that 
precluded the passage of  the conventional colonoscope 
(CF-Q160AL, Olympus Optical Co., Tokyo, Japan). A 
slim colonoscope (PCF-Q180AL Olympus Optical Co., 
Tokyo, Japan) was used to reach the terminal ileum. 
There were no endoscopic signs of  inflammation. The 
colon was shortened and showed extensive scarring and 
some inflammatory polyps; the ileal mucosa appeared to 
be normal. Dysplasia and malignancy were excluded by 
several biopsies of  the entire length of  the stricture.
A short cycle of  oral corticosteroids was completed, 
but the stricture was refractory to medical therapy, and 
the patient complained of  abdominal pain and experi-
enced a new episode of  bowel obstruction in September 
2011. After having discussed the therapeutic options in 
a gastrointestinal multidisciplinary team meeting, we de-
cided to place a SX-ELLA BD biodegradable esophageal 
stent (ELLA-CS, Hradec Kralove, Czech Republic; Fig-
ure 1) with a trunk diameter of  20 mm flaring to 25 mm 
at both ends and a length of  100 mm. The local ethics 
committee approved the procedure, and informed con-
sent was obtained from the patient.
The procedure was performed under conscious seda-
tion (intravenous midazolam) via an anal approach with 
the patient lying on her left side. Both margins of  the 
stricture were marked by using intramucosal lipiodol in-
jection. The stent was loaded into its dedicated 28 French 
delivery system and implanted under endoscopic and 
fluoroscopic guidance over a stiff  0.035-inch guidewire 
with a soft tip (Jagwire, Boston Scientific, Natick, United 
States) that was previously introduced through the stric-
ture. Pre-dilation was not performed. An adequate expan-
sion of  the stent occurred immediately after its insertion 
(Figures 2 and 3). Significant stent shortening occurred 
upon deployment, and a water-soluble contrast (Xenetix 
350, Guerbet Laboratories, Roissy, France) was injected 
at the end of  the procedure to confirm proper stent 
position and luminal patency. There were no immediate 
or delayed procedure-related complications, namely per-
foration, pain, hemorrhage or stent migration. The stent 
insertion provided rapid clinical improvement and symp-
tom relief, and the patient was discharged within 24 h.
A clinical and radiographic follow-up was performed 
one week after the stent insertion and again one month 
later, with no evidence of  stent migration. At that time, 
an endoscopy follow-up was also performed to monitor 
the stent patency and degradation. There was no signifi-
cant mucosal hyperplasic reaction and no resistance to 
the progression of  the conventional scope through the 
stent (Figure 2). Complete stent degradation was con-
firmed on a plain abdominal X-ray 4 mo after the inser-
tion (Figure 3). There was no recurrence of  the obstruc-
tive symptoms during a 16-mo follow-up. 
DISCUSSION
We report a case of  a patient with a long-standing CD 
who developed a symptomatic fibrotic stricture of  the 
colon despite optimized medical treatment with inflix-
imab and azathioprine. Fibrotic strictures in CD patients 
have been traditionally treated with intestinal resection, 
which is often extensive and associated with high morbid-
ity rates[5]. Furthermore, disease recurrence is common. 
Within 4 years, approximately 40% of  the patients will 
need another resection[6,7]. Concerns over short-bowel 
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Figure 1  SX-ELLA biodegradable biodegradable esophageal stent. The 
stent is flared at both ends to reduce the risk of migration and is fitted with ra-
diopaque markers at the midpoint and at the ends to enable precise stent posi-
tioning under fluoroscopic control. Because of reduced long-term elasticity, the 
stent is supplied separate from the delivery system and needs to be manually 
loaded just before the implantation procedure (see manufacturer’s “Instructions 
for Use”). 
syndrome caused by multiple resections and large seg-
ment resections led to the development of  bowel-sparing 
surgical techniques or strictureplasty, however, within 10 
years, up to 50% of  these patients will require repeated 
surgery because of  obstruction recurrence[8]. Facing the 
problems related to repeated surgery, endoscopic meth-
ods have been advocated for managing CD strictures. 
Balloon dilation (with or without steroid injection) is 
currently the endoscopic treatment of  choice. Several un-
controlled observational studies have shown that balloon 
dilation is a safe and effective alternative to surgery in se-
lected patients. It has and has a technical success rate that 
ranges from 71% to 90% and a major complications rate 
of  2% to 3%[9-11]. However, it is generally accepted that 
strictures greater than 4 cm are not amenable to balloon 
dilation, and the recurrence rate of  obstructive symptoms 
is as high as 42% with the need for repeated dilations and 
their associated perforation risk. 
Our patient was not a candidate for balloon dila-
tion because of  the extent of  the stricture, and surgical 
resection would likely have been extensive because of  
the scarring colon. Stent placement was thus consid-
ered. Compared with balloon dilation, stents determine 
slower and more sustained stricture dilation, resulting in 
reduced trauma and subsequent fibrosis. Furthermore, 
the radial force is maintained for several weeks, allow-
ing remodeling of  the stricture and increased long-term 
luminal patency with a reduced need for repeated dila-
tions. However, data regarding the efficacy and safety 
of  extractable SEMS in the treatment of  symptomatic 
intestinal strictures in CD are limited and conflicting[12-16]. 
In general, the use of  fully covered SEMS in this setting 
appears to be effective but has been associated with sev-
eral drawbacks and complications, such as a high rate of  
spontaneous migrations and the need for removal, and 
remains controversial. The recently developed biodegrad-
able stents are a promising option because of  their longer 
patency and no need for removal, although radial force is 
lower compared with nitinol stents.
Biodegradable stents are manufactured from differ-
ent synthetic polymers that have other well-established 
biomedical applications, particularly in the fields of  su-
tures, tissue engineering and controlled drug delivery. The 
polymers are degraded by random hydrolysis of  their 
molecules’ ester bounds, and the degradation products 
are metabolized via normal metabolic pathways. This pro-
cess compromises the structure and integrity of  the stent 
filaments and leads to the loss of  radial force, fracture of  
the stent skeleton and disintegration. The radial force of  
polydioxanone stents is maintained for approximately 6-8 
wk following implantation and drops to 50% by week 9. 
Disintegration usually occurs within 11-12 wk, although 
the degradation rate is dependent on the size, structure, 
temperature, pH and type of  body tissue in which the 
stent is implanted[17]. 
Biodegradable polydioxanone stents were developed 
and licensed for the treatment of  refractory benign 
esophageal strictures[18-22]. The experience with their use 
in intestinal strictures is encouraging but still in its early 
stages. Published information regarding intestinal bio-
degradable stenting is limited to a few small case series 
that are both prospective and retrospective and focus on 
patients with refractory anastomotic colorectal strictures 
following resection for rectosigmoid carcinoma[23-25]. Re-
jchrt et al[26,27] reported the placement of  biodegradable 
stents in patients with stricturing CD. This was the sole 
report of  such a use in the small bowel and proximal 
large bowel. Proximal stent insertion was accomplished 
by use of  a custom made introducer inserted into an 
overtube after endoscope removal. The standard delivery 
system for esophageal implantation has an active length 
of  75 cm and can only be used for intestinal strictures up 
to the distal descending colon.
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Figure 2  Endoscopic images. A: Stricture of the distal sigmoid colon before 
stent insertion. The surrounding mucosa show no signs of active inflammation 
and few inflammatory polyps; B: Biodegradable stent deployed in the stricture at 
the end of the procedure; C: Endoscopic view 1 mo after the stent placement. 
The stent fibers present a translucent appearance and partial fragmentation. 
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18 Fry SW, Fleischer DE. Management of a refractory benign 
esophageal stricture with a new biodegradable stent. Gastro-
Intestinal insertion of  biodegradable polydioxanone 
stents is technically possible and relatively simple. How-
ever, it has been associated with a significant rate of  early 
stent migration. This issue may be solved by improve-
ments in stent design and appropriate strategies such 
as clip placement in the upper flare of  the stents. It is 
necessary to clarify whether pre-dilation of  the stricture 
should be performed (unless there is an inability to pass 
the delivery system through the stricture) because the 
radial force of  biodegradable stents appears to be suffi-
cient to ensure adequate stent expansion. Severe mucosal 
hyperplastic reaction resulting in obstruction after bio-
degradable stenting has been documented in esophageal 
strictures[28,29] but not in intestinal strictures thus far. Most 
of  these cases were treated successfully with single bal-
loon dilation and resolved completely after stent degrada-
tion. Neither of  these complications was observed in our 
patient. 
In conclusion, early experience suggests that bio-
degradable polydioxanone stents may represent a new 
therapeutic option for CD patients with refractory bowel 
strictures or strictures in which balloon dilation is unsuit-
able. Further studies are necessary to fully assess their 
long-term efficacy and safety in this clinical setting.
REFERENCES
1 Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc 
R, Gendre JP. Long-term evolution of disease behavior of 
Crohn’s disease. Inflamm Bowel Dis 2002; 8: 244-250 [PMID: 
12131607 DOI: 10.1097/00054725-00207000-00002]
2 Van Assche G, Geboes K, Rutgeerts P. Medical therapy for 
Crohn’s disease strictures. Inflamm Bowel Dis 2004; 10: 55-60 
[PMID: 15058528 DOI: 10.1097/00054725-200401000-00009]
3 Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis 
J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, 
Kupcinskas L, Mantzaris G, Travis S, Stange E. The second 
European evidence-based Consensus on the diagnosis and 
management of Crohn’s disease: Definitions and diagnosis. 
J Crohns Colitis 2010; 4: 7-27 [PMID: 21122488 DOI: 10.1016/
j.crohns.2009.12.003]
4 Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The 
Montreal classification of inflammatory bowel disease: con-
troversies, consensus, and implications. Gut 2006; 55: 749-753 
[PMID: 16698746 DOI: 10.1136/gut.2005.082909]
5 Umanskiy K, Malhotra G, Chase A, Rubin MA, Hurst RD, 
Fichera A. Laparoscopic colectomy for Crohn’s colitis. A 
large prospective comparative study. J Gastrointest Surg 2010; 
14: 658-663 [PMID: 20127200]
Figure 3  Radiographic images. A: Stricture of the distal sigmoid 
colon outlined by luminal filling with barium using a rectal catheter 
(supine position); B: Biodegradable stent in situ immediately after in-
sertion (supine position). The stent is radiolucent, but the radiopaque 
markers at the midpoint and at the ends are visible (black arrows). 
The margins of the stricture are marked with lipiodol (white arrows); C: 
Disappearance of radiopaque markers at 4 mo confirming complete 
stent degradation (erect position).
CBA
Rodrigues C et al . BD stent for stricturing CD
269 May 16, 2013|Volume 5|Issue 5|WJGE|www.wjgnet.com
intest Endosc 1997; 45: 179-182 [PMID: 9041006 DOI: 10.1016/
S0016-5107(97)70244-X]
19 Tanaka T, Takahashi M, Nitta N, Furukawa A, Andoh A, 
Saito Y, Fujiyama Y, Murata K. Newly developed biode-
gradable stents for benign gastrointestinal tract stenoses: a 
preliminary clinical trial. Digestion 2006; 74: 199-205 [PMID: 
17341853]
20 Saito Y, Tanaka T, Andoh A, Minematsu H, Hata K, Tsuji-
kawa T, Nitta N, Murata K, Fujiyama Y. Usefulness of bio-
degradable stents constructed of poly-l-lactic acid monofila-
ments in patients with benign esophageal stenosis. World J 
Gastroenterol 2007; 13: 3977-3980 [PMID: 17663513]
21 Repici A, Vleggaar FP, Hassan C, van Boeckel PG, Romeo 
F, Pagano N, Malesci A, Siersema PD. Efficacy and safety 
of biodegradable stents for refractory benign esophageal 
strictures: the BEST (Biodegradable Esophageal Stent) study. 
Gastrointest Endosc 2010; 72: 927-934 [PMID: 21034894 DOI: 
10.1016/j.gie.2010.07.031]
22 Stivaros SM, Williams LR, Senger C, Wilbraham L, Laasch 
HU. Woven polydioxanone biodegradable stents: a new 
treatment option for benign and malignant oesophageal stric-
tures. Eur Radiol 2010; 20: 1069-1072 [PMID: 19921200 DOI: 
10.1007/s00330-009-1662-5]
23 Janík V, Horák L, Hnaníček J, Málek J, Laasch HU. Biode-
gradable polydioxanone stents: a new option for therapy-
resistant anastomotic strictures of the colon. Eur Radiol 2011; 
21: 1956-1961 [PMID: 21533633]
24 Repici A, Pagano N, Rando G, Carlino A, Vitetta E, Ferrara 
E, Strangio G, Zullo A, Hassan C. A retrospective analysis of 
early and late outcome of biodegradable stent placement in 
the management of refractory anastomotic colorectal stric-
tures. Surg Endosc 2013; Epub ahead of print [PMID: 23443478 
DOI: 10.1007/s00464-012-2762-x]
25 Pérez Roldán F, González Carro P, Villafáñez García MC, 
Aoufi Rabih S, Legaz Huidobro ML, Sánchez-Manjavacas 
Múñoz N, Roncero García-Escribano O, Ynfante Ferrús M, 
Bernardos Martín E, Ruiz Carrillo F. Usefulness of biodegrad-
able polydioxanone stents in the treatment of postsurgical 
colorectal strictures and fistulas. Endoscopy 2012; 44: 297-300 
[PMID: 22261748 DOI: 10.1055/s-0031-1291482]
26 Rejchrt S, Kopacova M, Bartova J, Vacek Z, Bures J. Intestinal 
biodegradable stents: Initial experience in the Czech Repub-
lic. Folia Gastroenterol Hepatol 2009; 7: 7-11
27 Rejchrt S, Kopacova M, Brozik J, Bures J. Biodegradable 
stents for the treatment of benign stenoses of the small and 
large intestines. Endoscopy 2011; 43: 911-917 [PMID: 21623562 
DOI: 10.1055/s-0030-1256405]
28 Orive-Calzada A, Alvarez-Rubio M, Romero-Izquierdo S, 
Cobo Martin M, Juanmartiñena JF, Ogueta-Fernández M, 
Molina-Alvarez E, Eraña-Ledesma L. Severe epithelial hy-
perplasia as a complication of a novel biodegradable stent. 
Endoscopy 2009; 41 Suppl 2: E137-E138 [PMID: 19544266 DOI: 
10.1055/s-0029-1214634]
29 Hair CS, Devonshire DA. Severe hyperplastic tissue stenosis 
of a novel biodegradable esophageal stent and subsequent 
successful management with high-pressure balloon dilation. 
Endoscopy 2010; 42 Suppl 2: E132-E133 [PMID: 20405380 DOI: 
10.1055/s-0029-1244011]
P- Reviewers  Mpoumponaris AM, Kim JW, Laasch HU 
S- Editor  Gou SX    L- Editor  A    E- Editor  Zhang DN
Rodrigues C et al . BD stent for stricturing CD
